<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836991</url>
  </required_header>
  <id_info>
    <org_study_id>RS-ADGC</org_study_id>
    <nct_id>NCT01836991</nct_id>
  </id_info>
  <brief_title>D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer</brief_title>
  <official_title>Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the effect of D2 and D2+ radical
      surgery for the treatment of advanced distal gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and the disease-free survival time(DFS) and overall survival time(OS)
      of D2 and D2+ radical surgery for the treatment of advanced distal gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the disease-free survival time</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the overall survival time</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>D2 surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2+ surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D2+ surgery(D2+8p、12b、13、14v lymph node)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <arm_group_label>D2 surgery</arm_group_label>
    <arm_group_label>D2+ surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 to 70 years old.

          -  The preoperative evaluation: distal gastric cancer patients, ≥ T2 or N +; or staging
             II, IIIA, IIIB.

          -  Karnofsky score ≥ 70, life expectancy &gt; 6 months.

          -  Endoscopic biopsy diagnosis of gastric cancer, excluding non-Hodgkin's lymphoma,
             leiomyosarcoma and other mesenchymal tumors.

          -  the blood and biochemical indicators of the subjects must meet the following criteria:
             Hb ≥ 9 g / dl; WBC ≥ 4,000 / mm3, ≤ 12000 / mm3; PLT ≥ 100,000/mm3;

          -  GOT, GPT within twice the institutional limit,serum total bilirubin &lt; 1.5 times the
             upper limit of normal, serum creatinine&lt; 1.25 times the upper limit of normal

          -  have not received prior chemotherapy, radiotherapy and biological therapy. signed
             informed consent.

          -  must accept the standard D2 or D2 + radical gastrectomy.

          -  with good compliance.

        Exclusion Criteria:

          -  pregnancy, breast-feeding women.

          -  allergy with chemotherapy drugs or metabolic disorder.

          -  the history of organ transplants (including bone marrow transplantation and autologous
             peripheral stem cell transplantation).

          -  had long received systemic steroid treatment (Note: short-term users of withdrawal &gt; 2
             weeks can be selected.)

          -  The existence of the peripheral nervous system disorders or significant neurological
             disorders and a history of central nervous system disorders.

          -  patients with severe infection requires treatment.

          -  patients associated with dysphagia, active peptic ulcer, incompleteness intestinal
             obstruction, active gastrointestinal bleeding, perforation.

        severe liver disease (such as cirrhosis), kidney disease, respiratory disease or
        uncontrollable diabetes.

          -  with other malignancies which were not cured.

          -  EKG abnormalities or heart disease with apparent clinical symptoms, including
             congestive heart failure, coronary heart disease with symptoms, uncontrollable
             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade
             myocardial infarction. Coronary heart disease with symptoms, uncontrollable
             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade
             myocardial infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiangdong Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiangdong Cheng, MD</last_name>
    <phone>+86 571 88122516</phone>
    <email>ypfzmu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou,</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiangdong Cheng</last_name>
      <phone>+86 571 88122516</phone>
      <email>ypfzmu@163.com</email>
    </contact>
    <investigator>
      <last_name>xiangdong Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>surgery safety</keyword>
  <keyword>effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

